{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:01:43Z","timestamp":1758816103327,"version":"3.41.2"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2025.1532414","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:24:24Z","timestamp":1737350664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes"],"prefix":"10.3389","volume":"16","author":[{"given":"Zachary","family":"Freyberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald A.","family":"Codario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"luad176","DOI":"10.1210\/jcemcr\/luad176","article-title":"Dopamine agonists as a novel \u201cCure\u201d for autoimmune diabetes","volume":"2","author":"Sahota","year":"2024","journal-title":"JCEM Case Rep 2"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dbi20-0017","article-title":"Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.8.1460","article-title":"Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention","volume":"24","author":"Pozzilli","year":"2001","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e3298","DOI":"10.1002\/dmrr.v36.5","article-title":"Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect \u03b2-cell function in LADA patients: A 1-year pilot study","volume":"36","author":"Zhang","year":"2020","journal-title":"Diabetes\/metabolism Res Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.2018.20.issue-6","article-title":"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials","volume":"20","author":"Pozzilli","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15660","article-title":"Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies","volume":"89","author":"Wexler","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2015.10.008","article-title":"A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters","volume":"10","author":"Lamos","year":"2016","journal-title":"Primary Care Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01304.x","article-title":"Bromocriptine: old drug, new formulation and new indication","volume":"12","author":"Holt","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.56070","article-title":"Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes","volume":"41","author":"Mahajan","year":"2009","journal-title":"Indian J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","article-title":"Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study","volume":"21","author":"Posawetz","year":"2021","journal-title":"BMC endocrine Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015520","article-title":"Metabolic effects of prolactin","volume":"13","author":"Pirchio","year":"2022","journal-title":"Front Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-12-0455","article-title":"Testosterone: a metabolic hormone in health and disease","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000086","article-title":"Testosterone and weight loss: the evidence","volume":"21","author":"Traish","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","article-title":"Effect of cabergoline on metabolism in prolactinomas","volume":"98","author":"Auriemma","year":"2013","journal-title":"Neuroendocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000321395","article-title":"New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse","volume":"92","author":"Garcia-Tornadu","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-018-2485-z","article-title":"Dopamine and serotonin receptors in hypothalamic POMC-neurons of normal and obese rodents","volume":"43","author":"Romanova","year":"2018","journal-title":"Neurochemical Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2290","article-title":"Concise review: cell-based therapies and other non-traditional approaches for type 1 diabetes","volume":"34","author":"Creusot","year":"2016","journal-title":"Stem Cells (Dayton Ohio)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9363543","DOI":"10.1155\/2022\/9363543","article-title":"Type 1 diabetes (T1D) and latent autoimmune diabetes in adults (LADA): the difference between a honeymoon and a holiday","volume":"2022","author":"Marcon","year":"2022","journal-title":"Case Rep Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e3207","DOI":"10.1002\/dmrr.v36.2","article-title":"The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno-metabolic mechanisms","volume":"36","author":"Zhong","year":"2020","journal-title":"Diabetes\/metabolism Res Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2011.8.446","article-title":"Beta-cell preservation Is weight loss the answer","volume":"8","author":"Mazza","year":"2011","journal-title":"Rev Diabetes Stud"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0344-6","article-title":"New roles for dopamine D(2) and D(3) receptors in pancreatic beta cell insulin secretion","volume":"25","author":"Farino","year":"2020","journal-title":"Mol Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41398-020-01171-z","article-title":"Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors","volume":"11","author":"Aslanoglou","year":"2021","journal-title":"Trans Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/me.2012-1101","article-title":"Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro","volume":"26","author":"Simpson","year":"2012","journal-title":"Mol Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/me.2012-1226","article-title":"Dopamine synthesis and D3 receptor activation in pancreatic beta-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations","volume":"26","author":"Ustione","year":"2012","journal-title":"Mol Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505560200","article-title":"Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion","volume":"280","author":"Rubi","year":"2005","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2337\/db22-0522","article-title":"Roles of pancreatic islet catecholamine neurotransmitters in glycemic control and in antipsychotic drug-induced dysglycemia","volume":"72","author":"Freyberg","year":"2023","journal-title":"Diabetes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148684","article-title":"Development of a rapid insulin assay by homogenous time-resolved fluorescence","volume":"11","author":"Farino","year":"2016","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"104771","DOI":"10.1016\/j.isci.2022.104771","article-title":"Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine","volume":"25","author":"Aslanoglou","year":"2022","journal-title":"iScience"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.01.029","article-title":"The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells","volume":"79","author":"de Leeuw van Weenen","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00432","article-title":"Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia","volume":"11","author":"Freyberg","year":"2017","journal-title":"Front Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2014.07.004","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","author":"Ballon","year":"2014","journal-title":"Trends Endocrinol metabolism: TEM"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025537","article-title":"Dopamine receptors in human adipocytes: expression and functions","volume":"6","author":"Borcherding","year":"2011","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M081000","article-title":"Dopamine D2 receptor upregulates leptin and IL-6 in adipocytes","volume":"59","author":"Wang","year":"2018","journal-title":"J Lipid Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03525-1","article-title":"Subcutaneous adipose tissue dopamine D2 receptor is increased in prediabetes and T2D","volume":"83","author":"Vranic","year":"2024","journal-title":"Endocrine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"101241","DOI":"10.1016\/j.molmet.2021.101241","article-title":"Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes","volume":"51","author":"Tavares","year":"2021","journal-title":"Mol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700442R","article-title":"AMPK in skeletal muscle function and metabolism","volume":"32","author":"Kj\u00f8bsted","year":"2018","journal-title":"FASEB J"},{"key":"B37","article-title":"Dopamine acts through distinct mechanisms in liver, adipose tissue and skeletal muscle regulating glucose uptake and insulin receptor and AMPK phosphorylation","volume":"63","author":"Tavares","year":"2020","journal-title":"Diabetologia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"Defronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3025","article-title":"The benefits and risks of testosterone replacement therapy: a review","volume":"5","author":"Bassil","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(03)00100-0","article-title":"Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells","volume":"3","author":"Ghosh","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/db24-0175","article-title":"Development of novel tools for dissection of central versus peripheral dopamine D2-like receptor signaling in dysglycemia","volume":"73","author":"Bonifazi","year":"2024","journal-title":"Diabetes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1532414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T10:50:32Z","timestamp":1737456632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1532414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":41,"alternative-id":["10.3389\/fendo.2025.1532414"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1532414","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"article-number":"1532414"}}